Company / Cash & Equivalents
Arcellx, Inc. Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$80.3M
FY2025
5-year range
$30.8M / $394.6M
FY2021-FY2025
Trend
-24.1%
vs FY2024
Sector context
#158 of 207
Health Care
What the data says
Arcellx, Inc.'s cash & equivalents of $80M is lower than 76% of companies in the Health Care sector (FY2025). Declined from $395M to $80M over the past 2 years.
Based on SEC 10-K filings.
$80M in FY2025 with a 3-year CAGR of +7.7%.
Declined from $395M to $80M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +7.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 207This company $80.3M Sector average $669.5M
▼
-88.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +7.7%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 24.1% year-over-year.
- Ranks #158 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.02 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $80.3M | -24.1% |
| FY2024 | $105.7M | -73.2% |
| FY2023 | $394.6M | +514.8% |
| FY2022 | $64.2M | +108.2% |
| FY2021 | $30.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026